Abstract: The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN).

Abstract: The present invention relates to methods and compositions for treating and evaluating metastatic conditions.

Abstract: The invention concerns the use of Lactobacillus casei in a composition for oral administration to enhance immunity specific to pathogenic micro-organisms. Said composition can in particular be a food or a food supplement.

Abstract: The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-?B, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.

Abstract: The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN).

Abstract: The present invention provides for the first time YY1, a transcription factor gene over-expressed and/or functionally overactive in human cancer. The present invention provides methods of diagnosing and providing a prognosis for cancer such as prostate cancer, as well as methods of drug discovery. YY1 is also a therapeutic target for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition of YY1 expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments, including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy.

Abstract: The present invention provides, for the first time, the finding that Smac/DIABLO is underexpressed in cancers such as renal cell carcinoma. In particular, the present invention provides methods of diagnosing and providing a prognosis for cancers that underexpress Smac/DIABLO, as well as methods of drug discovery to identify therapeutics useful when used alone or in combination with other cancer therapeutics. The present invention also provides methods of treating or inhibiting cancers that underexpresses Smac/DIABLO, in which potentiation of Smac/DIABLO expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy. Compositions, kits, and integrated systems for carrying out the diagnostic, prognostic, and therapeutic methods of the present invention are also provided.

Abstract: The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-?B, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.

Abstract: The present invention relates to alkyl lysophospholipid (ALP), and derivatives thereof, that are potent cytokine inducers and immunomodulatory agents. The immunomodulatory agents are administered to a subject having a condition characterized by an altered or aberrant cytokine activity such as, but not limited to, neoplasia, infectious diseases, chronic and acute immune diseases, autoimmunity, transplantation, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy.

Abstract: A method for treatment of conditions in a patient concerns the treatment of cancers, infectious diseases, and unwanted tissues by interferon-gamma (IFN-&ggr;), Nitric Oxide (NO), NO donors, or inducible nitric oxide synthase (iNOS), applied either individually or in combination. In addition, a method for treating a cancer, infectious diseases, and immunologicaly unwanted tissues in an individual by administering a therapeutically effective amount of NO, NO donors, or iNOS thereby inducing the cancer cells to undergo Fas and TNF receptor family-mediated cytotoxicity which may also be combined with the administration of immunotherapeutic and/or cytotoxic agents.